Tests AZD6234 for weight management in adults with obesity or overweight
Tests AZD6234 against placebo in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Key facts
- Where
- Ansārinagar, Calicut, Kolkata, Ludhiana, Meerut, and Surat, IndiaSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight, with or without type 2 diabetes. It tests the drug AZD6234 against placebo.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Body mass index of at least 28 kg/m², or at least 24 and less than 28 kg/m² with at least one weight-related health problem (such as type 2 diabetes, high blood pressure, sleep apnoea or knee osteoarthritis). Body weight stable (5% change or less) for at least 3 months.
- Earlier treatment
- At least one earlier unsuccessful attempt to lose weight. No weight-management treatment, GLP-1 medicine or amylin-based medicine in the 3 months before randomisation. People with type 2 diabetes must be on diet and exercise alone or on a stable dose of 1 to 3 oral glucose-lowering medicines for at least 3 months, and cannot use insulin.
- Biomarker or test result
- For people with type 2 diabetes: HbA1c between 6.0% (42 mmol/mol) and 10.0% (86 mmol/mol) at screening, and diabetes diagnosed at least 6 months before consent.
Main reasons for not taking part
- Type 1 diabetes, or obesity mainly caused by another hormone disorder
- Severe heart failure, or a heart event or heart procedure in the last 3 months
- Past or planned weight-loss surgery
- Unstable major depression, psychosis, bipolar disorder, or a past suicide attempt
- Currently pregnant or breastfeeding
Read by machine on 13 November 2026.
Where in India
- AnsārinagarHospital not named in the registryNo longer taking part
- CalicutHospital not named in the registryNo longer taking part
- KolkataHospital not named in the registryNo longer taking part
- LudhianaHospital not named in the registryNo longer taking part
- MeerutHospital not named in the registryNo longer taking part
- SuratHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07922330
- Record updated
- 6 November 2026
- Original description
This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.Read full original descriptionShow less
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE-Asia)
This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
Inclusion: Aged 18 years or older at the time of signing informed consent; Body mass index:; at least 28 kg/m²; or; at least 24 kg/m² and less than 28 kg/m² with at least one protocol-defined weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, knee osteoarthritis, or stress urinary incontinence; Stable body weight (≤ 5% body weight change) for at least 3 months prior to Randomisation; Participants with type 2 diabetes mellitus must:; have been diagnosed at least 6 months before informed consent; have HbA1c between 6.0% and 10.0% at Screening; and; be managed with diet and exercise alone or with a stable dose of 1 to 3 oral glucose-lowering medications for at least 3 months before Screening; At least one previous self-reported unsuccessful attempt to lose body weight; Participants of childbearing potential must comply with protocol-defined highly effective contraception requirements and have negative pregnancy tests at Screening and Randomisation; Able to provide signed informed consent.
Exclusion: Severe heart failure, defined as New York Heart Association Class IV, or hospitalisation for heart failure within 3 months before Screening; Type 1 diabetes mellitus or ketoacidosis or hyperosmolar coma/state within 3 months before Screening; Significant inflammatory bowel disease or another severe disease or prior surgery affecting the upper gastrointestinal tract; Cardiovascular event, percutaneous coronary intervention, or coronary artery bypass graft within 3 months before Screening; Previous or planned surgical treatment for obesity; Known or suspected drug abuse or alcohol abuse; Planned elective surgery requiring discontinuation of study intervention for more than 6 weeks; Weight-management treatment within 3 months before Randomisation; Treatment with a glucagon-like peptide-1 receptor agonist or another glucagon-like peptide-1-containing medication within 3 months before Randomisation; Treatment with a marketed or investigational amylin-based compound within 3 months before Randomisation; Concomitant medication that may increase risk, affect study results, or interfere with study participation; Participation in another clinical study within 30 days before Screening; Previous randomisation in the present study; Obesity primarily caused by another endocrine disorder; Neoplastic disease within 5 years before Screening, except as otherwise permitted by the protocol; Clinically important disease or disorder that may place the participant at risk or interfere with study participation; Use of insulin therapy for type 2 diabetes mellitus; Unstable major depressive disorder or Patient Health Questionnaire-9 score of 15 or higher; History of psychosis or active symptomatic bipolar disorder; Active suicidal ideation corresponding to Category 4 or 5 on the Columbia-Suicide Severity Rating Scale, or history of a suicide attempt; Known hypersensitivity to AZD6234; Any other condition that, in the Investigator's judgement, makes participation inappropriate; Significant hepatobiliary disease, including protocol-defined elevations in alanine aminotransferase, aspartate aminotransferase, or total bilirubin; Clinically significant gastric-emptying abnormality requiring treatment; Uncontrolled hypothyroidism or hyperthyroidism; Long-term systemic glucocorticoid treatment lasting more than 14 days or use of central nervous system stimulants; Involvement in the planning and/or conduct of the study; Unlikely or unable to comply with study procedures, restrictions, or requirements; Currently pregnant or breastfeeding.